Archive
591 articles, sorted by publication time.
A randomized deployment study of nearly 14,000 people brought medical AI from standardized tests into users’ real-time descriptions. The results offer rare field evidence, while also reminding readers that symptom interpretation remains institutionally and clinically distant from true diagnosis.
The latest review focus is not only whether another flu vaccine can reach the market, but whether the mRNA platform can prove in seasonal respiratory diseases that its speed, adaptability, and clinical benefit are enough to change the existing vaccine market.
In invasive aspergillosis, where treatment options are limited and nephrotoxicity often affects treatment decisions, F2G and Shionogi’s OASIS trial brings an oral drug with a new mechanism one step closer to a marketing application; however, the publicly available data are still topline results, and the full efficacy and safety profile remains to be disclosed at a medical meeting.
A small randomized trial in India showed that adding a daily probiotic supplement to existing antidepressant treatment may give older adults with depression slightly greater improvement in mood and anxiety symptoms; however, the evidence remains preliminary and should not be interpreted as support for replacing medication or psychotherapy on one’s own.
A Mayo Clinic team has turned a casual conversation between graduate students into a new tool: synthetic DNA aptamers can recognize surface features of senescent cells, paving the way for tracking and clearing aging-related cells, though there is still a long experimental road before human use.
An MIT mouse study suggests that a common amino acid may awaken intestinal stem cells through immune cells, offering a new dietary intervention concept for radiation therapy-induced intestinal mucosal injury; but key validation is still needed before any clinical recommendations.
Rare-disease diagnosis is often stalled by a long and fragmented puzzle of clues; LiteOdyssey, proposed in a new preprint, attempts to make AI not only provide answers, but also leave an inspectable reasoning path along the clinical genetics workflow.
A generic version of baloxavir marboxil has been approved for launch before the 2026 to 2027 flu season. Its significance lies not in changing the principles of treatment, but in potentially making a once-daily antiviral option more accessible in clinical and home-care settings.
The undisclosed acquisition is not truly a bet on a new drug already proven effective, but on a pain biology pathway that seeks to avoid opioids and central nervous system side effects.
A single oral drug has shown signals in both obstructive and non-obstructive hypertrophic cardiomyopathy, giving Edgewise a rationale to move into pivotal trials; but whether it can establish a clear position beyond existing cardiac myosin inhibitors remains a question for larger studies.
Talvey plus Darzalex Faspro opened a progression-free survival gap in a trial for relapsed or refractory multiple myeloma, adding a key piece of clinical evidence for moving bispecific antibodies into earlier lines of treatment.
A study in cells and nematodes places the common nutrient leucine within the precise circuitry of mitochondrial protein quality control. It points to a more direct molecular bridge between diet and cellular energy, but clinical application remains clearly distant.